NPPB, natriuretic peptide B, 4879

N. diseases: 193; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 GeneticVariation disease BEFREE Other cardiovascular complications seen in GBS patients were Increased pro-BNP(26.04%), raised troponin T levels(3.12%), acute coronary syndrome(2.08%), heart failure(2.08%) and abnormal 2D echo findings(8.33%). 31504947 2020
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE Progressive aortic constriction in growing pigs induces significant LV hypertrophy with cardiac fibrosis associated with left atrial dilation, raised filling pressures, and an ability to transition to overt HF with raised BNP without reduction in LVEF. 31851785 2020
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 GeneticVariation disease BEFREE Other cardiovascular complications seen in GBS patients were Increased pro-BNP(26.04%), raised troponin T levels(3.12%), acute coronary syndrome(2.08%), heart failure(2.08%) and abnormal 2D echo findings(8.33%). 31504947 2020
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 Biomarker disease BEFREE Progressive aortic constriction in growing pigs induces significant LV hypertrophy with cardiac fibrosis associated with left atrial dilation, raised filling pressures, and an ability to transition to overt HF with raised BNP without reduction in LVEF. 31851785 2020
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 AlteredExpression disease BEFREE The comparison of prognosis⁻predictivity of a single measurement of plasma NT-pro BNP in different follow-up periods in acute HF patients has been less studied. 30871208 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 AlteredExpression disease BEFREE Echocardiography and the expression of BNP showed that rivaroxaban attenuated heart failure. 30867376 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure. 30912456 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE The study included 46 patients with HF and implanted CRT-D. Levels of NT-pro BNP and cTnThs were assessed during a 12 month follow up. 31223080 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 AlteredExpression disease BEFREE Baseline rSO2 was lower in patients with heart failure (45.2±8.3 % vs. 54.1±7.8 %, p=0.006) and was significantly linked to higher red cell distribution width (RDW) (r=-0.53, p?0.001) and higher BNP level (r=-0.45, p=0.01). 31177793 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 AlteredExpression disease BEFREE Accompanying these effects, tadalafil treatment normalized BNP mRNA and prevented development of subjective signs of HF. 31043634 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE Change of BNP between admission and discharge after ST-elevation myocardial infarction (Killip I) improves risk prediction of heart failure, death, and recurrent myocardial infarction compared to single isolated measurement in addition to the GRACE score. 29359586 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE Receiver operating characteristic curve (ROC) analysis found that area under the ROC (AUC) was 0.616 (95%CI = 0.511-0.721, P = 0.034) when BNP was used to predict post-AMI HF, whereas AUC improved to 0.764 (95%CI = 0.674-0.855, P < 0.001) when miR-150 was used. 30745540 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE To develop a risk score to predict all-cause death for HFpEF patients, we examined 1277 HF patients with LVEF ≥50% and BNP ≥100 pg/ml in the CHART-2 Study, a large-scale prospective cohort study for HF in Japan. 30413304 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 AlteredExpression disease BEFREE The body weight, heart weight index (HWI), heart weight/tibia length ratio (HW/TL), and serum BNP level were investigated to assess the effect of LGZG on HF. 31829159 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE On multivariate analysis, admission initial stroke severity (OR 1.04, 95 CI% 1.004-1.07, p < 0.05) history of heart failure (OR 3.03, 95% CI 1.19-7.73, p < 0.05), ECG abnormalities and high BNP value (OR 4.34, 95% CI 2.59-7.29, p < 0.05) were associated with pure cardiac stroke mechanism. 29804788 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 AlteredExpression disease BEFREE Conclusions Analytical performances of the BNP and PBNP ADVIA methods are well in accordance with the quality specifications required by international guidelines for diagnosis and follow-up of patients with HF. 30412461 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 AlteredExpression disease BEFREE Patients with heart failure and CSA-CSR ± OSA have higher RRs but similar MV under ASV-therapy than patients with CSA and normal BNP. 29940592 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE Atrial and brain natriuretic peptides (ANP and BNP) are established diagnostic and prognostic markers in heart failure, but their utility in patients with advanced cancer is unclear. 31128228 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.600 Biomarker disease BEFREE Following the recommendation of natriuretic peptides (B-type natriuretic peptide and N-terminal-proBNP), many other biomarkers have been thoroughly studied to reflect different pathophysiological processes (such as fibrosis, inflammation, myocardial injury, and remodeling) in HF and some of them (like cardiac troponins, soluble suppression of tumorigenesis-2, and galectin 3) have subsequently been recommended to aid in the diagnosis and prognostication in HF. 31183637 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 Biomarker disease BEFREE Change of BNP between admission and discharge after ST-elevation myocardial infarction (Killip I) improves risk prediction of heart failure, death, and recurrent myocardial infarction compared to single isolated measurement in addition to the GRACE score. 29359586 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 Biomarker disease BEFREE NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure. 30912456 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 AlteredExpression disease BEFREE The body weight, heart weight index (HWI), heart weight/tibia length ratio (HW/TL), and serum BNP level were investigated to assess the effect of LGZG on HF. 31829159 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 AlteredExpression disease BEFREE Baseline rSO2 was lower in patients with heart failure (45.2±8.3 % vs. 54.1±7.8 %, p=0.006) and was significantly linked to higher red cell distribution width (RDW) (r=-0.53, p?0.001) and higher BNP level (r=-0.45, p=0.01). 31177793 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 Biomarker disease BEFREE The Sesn2 concentrations were positively correlated with N-terminal B-type natriuretic peptide (NT-pro BNP) but negatively correlated with left ventricular ejection fraction (LVEF) in CHF patients. 31059702 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.600 Biomarker disease BEFREE Assessment of GVRs revealed that the correctly trained model highlighted conventional radiographic features of CHF as reasons for an elevated BNP prediction more frequently than the overfitted model, including cardiomegaly (153 [76.5%] of 200 vs 64 [32%] of 200, respectively; P < .001) and pleural effusions (47 [23.5%] of 200 vs 16 [8%] of 200, respectively; P = .003). 30398431 2019